-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
M&A transactions are an important part of the biopharmaceutical industry, and M&A by pharmaceutical companies is mostly due to expanding pipelines and strengthening channels, which is a more efficient choice
than self-construction.
In 2022 overall, the M&A industry is
hotter than ever.
Compared to 2021, the number of acquisitions in the pharmaceutical industry has increased significantly this year, with a slight increase in average deal size
.
This article will take stock of the five largest M&A deals
in the biomedical industry this year.
in the biomedical industry this year.
01Amgen acquires Horizon for $27.
8 billion
8 billion
On December 12, Amgen agreed to acquire biotech star Horizon for $27.
8 billion
Therapeutics, which became the company's largest acquisition in history and the largest acquisition in the pharmaceutical industry this year, Amgen aims to strengthen its portfolio of rare disease drugs
.
8 billion this year
Founded in 2008 and launched in 2011, Horizon's product pipeline focuses on ophthalmology, rare diseases, immune diseases and inflammation
.
Through the acquisition, Amgen acquired two of Horizon's best-selling star products: one is Tepezza, which treats thyroid eye disease; The second is Krystexxa
, which treats gout.
02Pfizer acquires Biohaven for $11.
6 billion
6 billion
On May 10, Pfizer announced its $11.
6 billion acquisition of Biohaven
Pharma
。 Biohaven is a drug discovery company for neurological disorders and a leader in the field of migraine
.
Biohaven's blockbuster product is the migraine drug Nurtec
ODT (Rimegepant), the world's first and only calcitonin gene-associated peptide (CGRP) receptor antagonist with rapid dissolving oral disintegration tablet form, and the only drug
that can be used simultaneously to treat and prevent migraine.
With this acquisition, Pfizer has access to a range of promising CGRP receptor antagonists, including Nurtec
ODT, Zavegepant, and additional preclinical development
pipelines.
6 billion in migraine drug Nurtec ODT（Rimegepant）
03Pfizer acquires Global for $5.
4 billion
Blood
4 billion Blood
On August 8, Pfizer announced the acquisition of Global Blood for $5.
4 billion
Therapeutics（GBT）
。 Pfizer's hematology focus is sickle cell disease (SCD) and hemophilia, and the acquisition of GBT coincides with Pfizer's focus
.
GBT was founded in 2011 and specializes in the research and development
of therapeutic drugs for SCD.
Its flagship product is Oxbryta (voxelotor), a drug
that directly targets the root cause of SCD.
In 2019, it received accelerated FDA approval for the treatment of adults and adolescents over 12 years of age, becoming the first innovative therapy to inhibit the polymerization process of hemoglobin, and won the Galen Prize
, known as the "Nobel Prize in Medicine" in 2021.
The acquisition complements and further strengthens Pfizer's more than 30 years of experience in rare hematology and strengthens the company's commitment to SCD by bringing expertise and a leading portfolio and product line that promises to address all critical needs
in this unmet disease area.
4 billion for SCDOxbryta (voxelotor)
04Bristol-Myers Squibb acquires Turning for $4.
1 billion
Point
1 billion Point
On June 3, Best-Myer Squibb (BMS) announced the acquisition of clinical-stage oncology biopharmaceutical company Turning for $76 per share (totaling $4.
1 billion).
Point Therapeutics
。 Turning
Point is a clinical-stage precision oncology company that targets the most common mutations
associated with cancer.
The company's most significant assets are the next generation of potential blockbuster tyrosine kinase inhibitors (TKIs), non-small cell lung cancer (NSCLC), and drugs
targeting other advanced solid tumors, ROS1 and NTRK.
Turning
The Point product line includes Repotrectinib, TPX-0022, TPX-0046 and the next-generation ALK inhibitor TPS-O131
.
Its core asset, Repotrectinib, belongs to a class known as tyrosine kinase inhibitors
kinase inhibitors), which are currently being tested for the treatment of non-small cell lung cancer (NSCLC) and other advanced solid tumors
.
1 billion in precision oncology core asset Repotrectinib
BMS believes it acquired Turning
With the addition of best-in-class precision oncology assets to Point, BMS will further expand its priority in oncology, and this acquisition will be an important step
in achieving business growth.
05Amgen acquires ChemoCentryx for $3.
7 billion
7 billion
On August 4, Amgen and ChemoCentryx jointly announced that the two companies have reached a definitive agreement to acquire ChemoCentryx
for approximately $3.
7 billion.
The acquisition gives Amgen access to ChemoCentryx's "first-in-class" drug Tavneos and strengthens its inflammatory and kidney disease pipeline
.
ChemoCentryx is a biopharmaceutical company focused on discovering, developing, and commercializing oral therapies for the treatment of autoimmune, inflammatory and cancerous diseases, with a primary focus on rare diseases
.
Its core product, Tavneos (avacopan), is a "first-in-class" orally selective complement 5a receptor (C5aR) inhibitor
.
In addition to Tavneos, ChemoCentryx has 3 early-stage drug candidates targeting other inflammatory diseases, as well as 1 oral checkpoint inhibitor
for tumors.
Through the acquisition of ChemoCentryx
With its drug Tavneos, Amgen further solidifies its leadership in inflammation and nephrology
.
7 billion core product Tavneos (avacopan)
Information Reference:
Information Reference:The official website of each company
The official website of each company
